Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • Searching Asian documents: patent search and monitoring services
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet and OPS
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Patent insight reports
    • Data
      • Overview
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge

    UP search

    Learn about the Unitary Patent in patent knowledge products and services

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Find a professional representative
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Unitary Patent

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • EPC Guidelines
      • PCT-EPO Guidelines
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National law relating to the UP
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives

    legal text

    Legal texts

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2022 ceremony
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Firefighting technologies
      • Green tech in focus
      • CodeFest on Green Plastics
      • Clean energy technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    Listen to our podcast

  • Learning

    Learning

    The e-Academy – the point of access to your learning

    Go to overview 

    • Overview
    • European Patent Academy
      • Overview
      • Learning activities
      • Learning paths
    • Professional hub
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by area by profile
      • Overview
      • Business and IP managers
      • EQE candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)

    European Patent Academy

    Boost your IP knowledge with (e-)training from the European Patent Academy

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • A glimpse of the planned activities
      • Kids’ collaborative art competition
      • 50 Leading Tech Voices
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Governance
      • Overview
      • Communiqués
      • Calendar
      • Select Committee documents
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Public consultation on the EPO's Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Social responsibility
      • Overview
      • Environment and sustainability
      • Art collection
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s

    about us

    Patent Index 2022

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
  • New to patents
    • Go back
    • Overview
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Your business and patents
    • Is it patentable?
    • Are you first?
    • Why do we have patents?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • Searching Asian documents
      • EP full-text search
      • Bibliographic coverage in Espacenet and OPS
      • Full-text coverage in Espacenet
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
            • Go back
            • Overview
            • BG - Federated Register Service
            • GB - Federated Register Service
            • NL - Federated Register Service
            • MK - Federated Register Service
            • ES - Federated Register Service
            • GR - Federated Register Service
            • SK - Federated Register Service
            • FR - Federated Register Service
            • MT - Federated Register Service
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Searching Asian documents
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Patent insight reports
    • Data
      • Go back
      • Overview
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
          • Go back
          • EBD files (weekly download) - free of charge
            • Go back
            • Secure EBD ST.36 files (weekly download) - for national patent offices only
        • Boards of Appeal decisions
        • EP full-text data for text analytics
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Helpful resources
      • Go back
      • Overview
      • First time here? Patent information explained.
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Unitary Patent Guide
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Online Filing 2.0 pilot
        • MyEPO Portfolio - pilot phase
        • Online Filing 2.0 pilot continuation
        • Exchange data with us using an API
      • Get access
        • Go back
        • Overview
        • Installation and activation
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact on your files
      • Online Filing & fee payment outages
      • Tutorials
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • EPC Guidelines
        • Go back
        • Overview
        • Archive
      • PCT-EPO Guidelines
        • Go back
        • Overview
        • Archive
      • Guidelines revision cycle
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • Watch the 2023 ceremony
      • European Inventor Network
        • Go back
        • Activities granted in 2023
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • CodeFest on Green Plastics
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • IP and youth
      • Research institutes
      • Women inventors
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Patents and standards
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • European Patent Academy
      • Go back
      • Overview
      • Learning activities
      • Learning Paths
    • Professional hub
      • Go back
      • Overview
      • EPAC - European patent administration certification
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Archive
        • Candidates successful in the European qualifying examination
        • Compendium
          • Go back
          • Overview
          • Pre-examination
          • Paper A
          • Paper B
          • Paper C
          • Paper D
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
        • Go back
        • Overview
        • Patent enforcement in Europe
        • Patent litigation in Europe
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventors' handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
            • Go back
            • Overview
            • Is the idea ‘obvious’?
            • Prior art searching
            • Professional patent searching
            • Simple Espacenet searching
            • What is prior art?
            • Why is novelty important?
          • Competition and market potential
            • Go back
            • Overview
            • Research guidelines
          • Assessing the risk ahead
            • Go back
            • Overview
            • Exploitation routes
            • Significant commercial potential
            • Significant novelty
            • What about you?
            • What if your idea is not novel but does have commercial potential?
          • Proving the invention
            • Go back
            • Overview
            • Help with design or redesign
            • Prototype strategy
          • Protecting your idea
            • Go back
            • Overview
            • Forms of IPR
            • Patenting strategy
            • The patenting process
          • Building a team and seeking funding
            • Go back
            • Overview
            • Building a team
            • Sources of funding
            • Sources of help for invention
          • Business planning
            • Go back
            • Overview
            • Constructing a business plan
            • Keep it short!
          • Finding and approaching companies
            • Go back
            • Overview
            • First contact
            • Meetings
          • Dealing with companies
            • Go back
            • Overview
            • Advance or guaranteed payment
            • Companies and your prototype
            • Full agreement – and beyond
            • Negotiating a licensing agreement
            • Reaching agreement
            • Royalties
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • For IP professionals
          • For business decision-makers
          • For stakeholders of the innovation ecosystem
        • IP clinics
      • EQE Candidates
        • Go back
        • Overview
        • Coffee-break questions
        • Daily D questions
        • European qualifying examination - Guide for preparation
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Overview
      • 50 Leading Tech Voices
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Governance
      • Go back
      • Overview
      • Communiqués
        • Go back
        • Overview
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • About eTendering
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • Invoicing
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • EPO Data Hub
      • Clarification on data sources
    • Social responsibility
      • Go back
      • Overview
      • Environment
      • Art collection
        • Go back
        • Overview
        • The collection
        • Let's talk about art
        • Artists
        • Media library
        • What's on
        • Publications
        • Contact
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Procedure
    • Annual reports
      • Go back
      • Overview
    • Organisation
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
        • Composition of the Presidium
          • Go back
          • Overview
          • Archive
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2023
      • Archive
    • Annual list of cases
    • Communications
    • Publications
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
    • Case Law from the Contracting States to the EPC
    • Oral proceedings
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Legal resources
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
      • Specific contact
      • Surveys
        • Go back
        • Overview
        • Search services
        • Examination services, final actions and publication
        • Opposition services
        • Patent filings
          • Go back
          • Overview
          • Detailed methodology
          • Archive
        • Online Services
        • Patent information
          • Go back
          • Overview
          • Innovation process survey
        • Customer services
        • Filing services
        • Website
        • Survey on electronic invoicing
        • Companies innovating in clean and sustainable technologies
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Forums
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2023 decisions
  • 2022 decisions
  • 2021 decisions
https://www.epo.org/en/node/t151729eu1
  1. Home
  2. T 1729/15 (Neisseria meningitidis combination vaccines/GLAXOSMITHKLINE) 05-02-2019
Facebook Twitter Linkedin Email

T 1729/15 (Neisseria meningitidis combination vaccines/GLAXOSMITHKLINE) 05-02-2019

European Case Law Identifier
ECLI:EP:BA:2019:T172915.20190205
Date of decision
05 February 2019
Case number
T 1729/15
Petition for review of
-
Application number
10007477.2
IPC class
A61K 39/095
A61K 39/385
A61P 31/04
C12P 19/04
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 380.6 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Neisseria meningitidis combination vaccines

Applicant name
GlaxoSmithKline Biologicals SA
Opponent name
Pfizer Inc.
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 56
Keywords
Main request, auxiliary request 1 - inventive step (no)
Catchword
-
Cited decisions
G 0009/92
T 0606/89
Citing decisions
-

I. The appeal of the patent proprietor (appellant) lies against the interlocutory decision of the opposition division that European patent No. 2 263 688 can be maintained in amended form.

II. The patent is entitled "Neisseria meningitidis combination vaccines" and was granted in respect of European patent application No. 10 007 477.2, a divisional application of European patent application No. 06 075 175.5, which in turn is a divisional application of European patent application

No. 02 755 452.6, filed on 20 June 2002. The patent claims the priority of GB application No. 0 115 176, filed on 20 June 2001.

III. An opposition was filed against the patent. The patent was opposed under Article 100(a) EPC on the grounds of lack of novelty (Article 54 EPC) and lack of inventive step (Article 56 EPC), under Article 100(b) and

100(c) EPC.

IV. The opposition division decided that the subject-matter of the main request (claims as granted) did not extend beyond the content of the (earlier) application as filed and that the patent disclosed the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. However, it held that the subject-matter of claims 1, 2, 3, 7 and 10 lacked novelty (Article 54 EPC). The subject-matter of claim 1 of auxiliary request 1 was found to lack an inventive step (Article 56 EPC). The patent was

maintained in amended form on the basis of the set of claims of auxiliary request 2 and an adapted description.

V. With the statement of grounds of appeal the appellant filed a main request and auxiliary requests 1 and 2. These claim requests were the same as the claim requests underlying the decision under appeal.

Claim 1 of the main request and of auxiliary requests 1 and 2 read as follows:

"1. A kit comprising: (a) conjugated capsular oligosaccharide from N.meningitidis serogroup A, in lyophilised form; and (b) one or more further antigens in liquid form."

"1. A kit comprising: (a) conjugated capsular oligosaccharide from N.meningitidis serogroup A, in lyophilised form, wherein the serogroup A saccharide has an average degree of polymerisation of between 10 and 20; and (b) one or more further antigens in liquid form."

"1. A kit comprising: (a) conjugated capsular oligosaccharide from N.meningitidis serogroup A, in lyophilised form; and (b) one or more further antigens in liquid form, wherein component (b) comprises a saccharide antigen from Haemophilus influenzae B and/or wherein the further antigen in component (b) is conjugated capsular oligosaccharide from N.meningitidis serogroup C."

VI. The opponent filed a notice of appeal and subsequently withdrew its appeal.

VII. In response to the statement of grounds of appeal, the opponent (respondent) submitted that the opposition division's decision "was fully justified and we have no further comments at this time".

VIII. The board issued a summons to oral proceedings accompanied by a communication pursuant to

Article 15(1) RPBA informing the parties that the respondent's submission in reply to the statement of grounds of appeal (see section VII above) was understood by the board as an implicit request to dismiss the appeal.

In a further communication pursuant to

Article 15(1) RPBA the board set out its preliminary opinion that the subject-matter of claims 1 of the main request and of auxiliary request 1 lacked an inventive step.

IX. Both the appellant and the respondent informed the board that they would not attend the oral proceedings. The appellant also withdrew the request for oral proceedings.

X. Oral proceedings before the board were held on 5 February 2019. The parties were not present or represented, as stated beforehand in writing. At the end of the oral proceedings, the Chair announced the board's decision.

XI. The following documents are referred to in this decision:

D1 WO02/00249 (3 January 2002)

D3 Costantino P. et al., Vaccine (1992), vol. 10,

pages 691 to 698

D5 Ravenscroft N. et al., Vaccine (1999), vol. 17,

pages 2802 to 2816

D17 Lei Q.P. et al., in Brown F., Corbel M.,

Griffiths E. (eds): Physico-Chemical Procedures

for the Characterization of Vaccines.

Dev. Biol. Basel, Karger (2000), vol. 103,

pages 259 to 264

XII. The appellant's arguments relevant to the present decision, submitted in writing, may be summarised as follows:

Main request

Novelty (Article 54(2) EPC) - claim 1

Document D1 did not anticipate the claimed subject-matter because feature (a) of the claim was not disclosed directly and unambiguously in that document.

It was necessary to make a triple selection in the embodiment described on page 5, lines 18 to 25 of document D1 to arrive at the claimed subject-matter.

Firstly, it was necessary to select that the MenA antigen referred to in the passage was a capsular saccharide antigen.

Secondly, it was necessary to select the use of a capsular oligosaccharide antigen in the specific embodiment recited on page 5, rather than the polysaccharide antigens described throughout the description, as the most preferred form of antigen. In order to select this feature the skilled person would have to turn to page 10, lines 20 to 25 of document D1.

Thirdly, it was necessary to select that the MenA antigen in particular was an oligosaccharide as opposed to selecting one or more of the other polysaccharides required in the embodiment on page 5 to be replaced with an oligosaccharide.

Inventive step (Article 56 EPC) - claim 1

Closest prior art

The closest prior art for the subject-matter of the main request was document D17 or document D3, and not document D1 as suggested in the decision under appeal.

The purpose of the invention was the preparation of multivalent vaccines comprising a Neisseria meningitidis serogroup A (MenA) antigen. All three documents D1, D3 and D17 had this purpose and therefore it could not be determined on this criterion alone which of the documents was the appropriate choice of closest prior art.

The opposition division incorrectly considered the number of common features between the prior art and the claimed invention before attempting to distinguish between the three prior art documents, based on the similarity of the effect provided by the disclosures in the prior art and the claimed invention - as required by decision T 606/89.

The effect provided by the claimed invention was the increased stability of conjugated MenA oligosaccharide. Data demonstrating the stability of a MenA conjugate in a liquid tetravalent Neisseria meningitidis vaccine containing antigens from serogroups A, C, W and W (MenACWY vaccine) were provided and compared with the stability of a MenA conjugate in a tetravalent MenACWY vaccine in which the MenA conjugate was lyophilised and the further three antigens were in liquid form. The comparison showed that lyophilisation of the MenA conjugate provided superior stability of the MenA conjugate when compared to a vaccine in fully liquid form.

Document D17 was the most promising starting point because it specifically considered the stability of Neisseria meningitidis (meningococcal) polysaccharide conjugate vaccines.

Document D1 could not be considered to be the closest prior art inter alia because it did not relate to stability and therefore did not demonstrate the same effect as the claimed invention. It also did not give any reason as to why lyophilised MenA antigen was used.

If document D17 was not considered to be the closest prior art because the same effect was not the primary criterion, and the number of differences between the subject-matter of the main request and the prior art documents were considered to be more relevant, then document D1 was still not the closest prior art. This was document D3, because the relevant subject-matter disclosed in document D1 had fewer features in common with the claimed subject-matter than that disclosed in document D3. While document D1 differed from the claimed invention in that the MenA antigen was not disclosed as being (i) conjugated, (ii) capsular and (iii) an oligosaccharide, the subject-matter disclosed in document D3 seemed to differ by only one feature, namely in that the MenA antigen was not lyophilised.

Technical problem and its solution

The difference between the claimed subject-matter and that disclosed in document D3 or D17 was that, in the kit, the MenA antigen was in lyophilised form, whilst the other antigens of the vaccine were retained in liquid form, whereas in prior art documents D3 or D17 all antigens in the kit were in liquid form.

The effect of this difference was the increased stability of the vaccine.

Therefore, the objective technical problem in view of the disclosure of document D3 or D17 was to provide an improved vaccine in terms of better stability comprising a conjugated MenA antigen.

Obviousness of the claimed solution

Starting from document D17 or D3, the skilled person would not have considered using lyophilised MenA conjugate, whilst retaining some or all of the other antigens in a liquid form, in order to provide a vaccine with improved stability.

Document D1 was the only document that mentioned lyophilisation, but it did not mention the purpose of the lyophilisation of the vaccine components.

Auxiliary request 1

Inventive step (Article 56 EPC) - claim 1

The subject-matter of claim 1 of auxiliary request 1 was inventive for the same reasons as explained for the main request.

Document D17 remained the most appropriate choice of the closest prior art because it related to the same effect as the claimed subject-matter.

If the closest prior art were to be identified primarily based on the number of features in common with the claimed subject-matter, then document D5 was a more appropriate choice as the closest prior art. Document D5 related to meningococcal capsular oligosaccharides used to prepare conjugate vaccines. A pool of MenA oligosaccharides, which had an average degree of polymerisation of 15.7, i.e. a degree which fell within the range claimed in auxiliary request 1, was used for conjugation to the carrier protein CRM197. The only difference between the subject-matter of

claim 1 and that of document D5 was the feature that the MenA conjugate was lyophilised.

Therefore, the number of features distinguishing the claimed subject-matter and the disclosure of document D5 (one) was smaller than the number of features distinguishing the claimed subject-matter and the disclosure of either of documents D1 or D3 (at least two) and therefore document D5 was a more appropriate choice as the closest prior art.

Starting from document D5, the skilled person would not have considered producing a multivalent vaccine kit in which the MenA conjugate was lyophilised, whilst some

or all of the other antigens were retained in liquid form, in order to provide a vaccine with improved stability.

XIII. The respondent did not file any arguments during the appeal proceedings.

XIV. The appellant requested that the decision under appeal be set aside and that the patent be maintained on the basis of the set of claims of the main request, or, alternatively, on the basis of the set of claims of auxiliary request 1 and a description adapted thereto, or on the basis of the set of claims of auxiliary request 2 and the adapted description filed during the oral proceedings before the opposition division.

The respondent requested that the appeal be dismissed.

1. The appeal complies with Articles 106 to 108 and Rule 99 EPC and is therefore admissible.

2. The opponent filed a notice of appeal and subsequently withdrew its appeal. Accordingly, the opponent is the respondent in these appeal proceedings.

3. The duly summoned parties were neither present nor represented at the oral proceedings. The board decided to continue the proceedings without the parties in accordance with Rule 115(2) EPC and treated them as relying on their written case in accordance with Article 15(3) RPBA.

Main request

Novelty (Article 54(2) EPC) - claim 1

4. The opposition division considered that the claimed subject-matter was not entitled to the claimed priority and that the effective date of the claimed subject-matter was thus the filing date. Therefore, document D1 belonged to the state of the art pursuant to

Article 54(2) EPC. This document was considered to anticipate the subject-matter of inter alia claim 1 (see decision under appeal, Reasons, points 3.3, 3.4 and 4).

5. The appellant does not contest that the claimed subject-matter is not entitled to claim priority but argues that the feature of the MenA antigen specifically being a conjugated capsular oligosaccharide is not directly and unambiguously disclosed in document D1.

6. The board concurs with the appellant that document D1 does not disclose the subject-matter of claim 1 of the main request.

7. However, the board disagrees with the appellant with regard to the extent of the disclosure of document D1. In the board's view, the reference to "MenA" on page 5, line 20 would be understood by the skilled person to refer to "N. meningitidis serogroup A capsular polysaccharide", see also page 8, lines 18 to 19 of document D1. This understanding is further supported by page 12, lines 1 to 12 of document D1.

8. Therefore, the board considers that document D1 discloses directly and unambiguously on page 5, lines 18 to 25, a kit comprising conjugated capsular polysaccharide from N. meningitidis serogroup A, in lyophilised form, and one or more further antigens in liquid form.

9. In view of the above analysis, the board concludes that the subject-matter of claim 1 fulfils the requirements of Article 54 EPC.

Inventive step (Article 56 EPC) - claim 1

Closest prior art

10. In the decision under appeal, document D1 was considered to be the closest prior art in relation to the subject-matter of claim 1 of auxiliary request 1, because it dealt with the same general problem, i.e. the production of multi-component vaccines and because the relevant subject-matter had the highest number of structural features in common with the claimed subject-matter (see Reasons, point 7.5).

11. The appellant does not dispute that the purpose of the invention is the preparation of multivalent vaccines comprising an antigen from Neisseria meningitidis serogroup A (MenA antigen) and that all three

documents D1, D3 and D17 relate to this purpose, but submits that it cannot be determined on this criterion alone which of these documents is the most appropriate choice as the closest prior art. Thus, before considering the commonality of technical features, the effect achieved by the claimed invention should be taken into account as agreed by the board in

decision T 606/89.

12. According to the established jurisprudence of the Boards of Appeal the closest prior art for assessing inventive step is normally a prior art document which discloses subject-matter conceived for the same purpose or with the same objective as the claimed invention and having the most relevant technical features in common, i.e. requiring the minimum of structural modifications (see Case Law of the Boards of Appeal of the European Patent Office, 8th edition 2016, I.D.3.1).

13. In the board's view, contrary to the submissions of the appellant, it cannot be derived from decision T 606/89 that to determine the closest prior art, a distinction should be made between documents based on the actual effect provided by the subject-matter as disclosed in the prior art and the claimed invention before assessing the commonality of technical features. Rather, also in this decision the same criteria set out in point 12, above, are taken into account to establish the closest prior art (see Reasons, point 2).

14. Given that, as agreed by the appellant, the purpose that can be derived from the relevant documents - documents D1, D3 and D17 - is the same as that of the claimed invention, the board will now determine the differences in the technical features (see point 12 above).

15. The kit disclosed in document D1 differs from the claimed kit in respect of just one feature, i.e. in that in the conjugate, the capsular saccharide component from the Neisseria meningitidis serogroup A (MenA) is a polysaccharide and not an oligosaccharide (see point 8 above).

16. Document D3 discloses a liquid formulation comprising capsular MenA and MenC oligosaccharides coupled to CRM197 (see abstract and page 693, left hand column, third paragraph). This formulation differs from the compounds in the kit as claimed in two aspects, i.e. in that (i) the MenA oligosaccharide is not lyophilised and in that (ii) it is already mixed with the further antigen MenC.

17. Document D17 discloses a liquid tetravalent vaccine comprising polysaccharides from Neisseria meningitidis serotypes A, C, W and Y which are individually linked to diphtheria toxoid (see page 259, last paragraph to page 260, second paragraph). This vaccine differs from the compounds in the kit as claimed in that (i) the saccharide component of the MenA conjugate is a polysaccharide and not an oligosaccharide, in that (ii) the conjugate is not lyophilised and (iii) is already mixed with the further antigens.

18. In view of the above analysis the board concludes that document D1 satisfies the established criteria - same purpose and requiring the minimum of structural modifications (see point 12) - to qualify as the closest prior art.

Technical problem

19. The subject-matter of claim 1 differs from the disclosure of document D1 in that the saccharide component of the conjugate is an oligosaccharide (see point 15).

20. There are no submissions in the proceedings by the appellant regarding the technical effect linked to this particular difference, this being due to the fact that the appellant's line of argument was confined to submitting that either document D3 or D17 was the closest prior art and that the relevant subject-matter disclosed therein differed from the claimed subject-matter in that the MenA antigen was in lyophilised form.

21. Accordingly, the board is of the opinion that starting from document D1 as the closest prior art, the problem to be solved can be seen as that of providing an alternative kit comprising a conjugated capsular saccharide from Neisseria meningitidis serogroup A, in lyophilised form, and one or more further antigens in liquid form.

Obviousness of the claimed solution

22. It needs to be established whether or not the skilled person, starting from the teaching in document D1 and faced with the objective technical problem as formulated in the preceding point, would have modified the teaching in the closest prior art document D1 in the light of other teachings in the prior art so as to arrive at the claimed invention.

23. Document D1 already mentions that instead of bacterial polysaccharides, bacterial oligosaccharides, "which are well known in the vaccine art", can be used (see page 10, lines 20 to 25).

24. The skilled person working in the field of vaccines is also aware of the disclosure of document D5. This document concerns the development of saccharide-conjugate vaccines against Haemophilus influenza type b (Hib) and Neisseria meningitidis serogroups A and C. The document discloses that the vaccines consist of oligosaccharides covalently attached to CRM197 and that the preparation of MenA oligosaccharides has an average degree of polymerisation (DP) of 15.7 (see abstract; page 2802, right hand column, lines 1 to 12; page 2803, right hand column, section 2.3 and page 2810, section 3.7).

25. In the board's judgement, the teaching of document D1 (see point 23 above) would have prompted the skilled person to replace the MenA polysaccharide in the kit of document D1 with the MenA oligosaccharide known from document D5. The skilled person would thus have arrived at the claimed invention in an obvious manner.

26. The board concludes from the above analysis that the subject-matter of claim 1 fails to meet the requirements of Article 56 EPC.

Auxiliary request 1

Inventive step (Article 56 EPC) - claim 1

Closest prior art

27. The subject-matter of claim 1 of auxiliary request 1 differs from the subject-matter of claim 1 of the main request in that "the serogroup A saccharide has an average degree of polymerisation of between 10 and 20" (see section V).

28. The appellant submitted that document D17 remained the most appropriate choice of closest prior art, but that, if the closest prior art was to be identified based on the document with the greatest number of features in common, then it was document D5 that qualified as the closest prior art. The number of features distinguishing the claimed subject-matter and that disclosed in document D5 (one) was smaller than the number of features distinguishing the claimed subject-matter and that disclosed in document D1 (at least two).

29. However, in the board's view, the vaccines disclosed in document D5 (see also point 24) differ from the claimed invention in two features rather than one, namely in that (i) the oligosaccharide from Neisseria meningitidis serogroup A is not lyophilised and (ii) in that it is already mixed with the further antigens.

30. The kit disclosed in document D1 differs from the claimed invention in that the saccharide component of the MenA conjugate is a polysaccharide and not an oligosaccharide having a certain DP.

31. In the board's view, document D1 is thus also the closest prior art to the subject-matter of claim 1 of auxiliary request 1 because it satisfies the established criteria - same purpose and requiring the minimum of structural modifications (see point 12) - in respect of this invention as well.

Technical problem and its solution, obviousness

32. In the board's view, the analysis set out above for the subject-matter of claim 1 of the main request (see points 22 to 26) applies, mutatis mutandis, to the subject-matter of claim 1 of auxiliary request 1. Thus, the skilled person would arrive in an obvious manner at a kit comprising a conjugated capsular oligosaccharide from Neisseria meningitidis serogroup A, in lyophilised form, wherein the serogroup A saccharide has an average DP of 15.7 and, thus, would arrive at an embodiment falling within the scope of claim 1 which defines the serogroup A saccharide as having an average DP of between 10 and 20.

33. Therefore, the subject-matter of claim 1 as a whole fails to meet the requirements of Article 56 EPC.

Auxiliary request 2

34. This request corresponds to the amended form of the patent considered allowable in the decision under appeal.

35. Since the patent proprietor is the sole appellant, the board has no power to review the decision under appeal as regards auxiliary request 2 because of the principle of prohibition of reformatio in peius (see decision

G 9/92, OJ EPO 1994, 875, Headnote I).

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • FAQ
    • Contact us
    • Subscription centre
    • Official holidays
    • Publications
    • Procedural communications
    • Ordering
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
SoMe facebook 0
European Patent Office
EPO Jobs
SoMe instagram
EuropeanPatentOffice
SoMe linkedIn
European Patent Office
EPO Jobs
EPO Procurement
SoMe twitter
EPOorg
EPOjobs
SoMe youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility